All In Biotech

Drug Trial Radar · NCT05841394

A Multi-center, Double-blinding, Parallel and Positive-controlled Phase III Clinical Trial for Efficacy and Safety Evaluation of Ilaprazole Sodium for Injection on Prevention of Stress Ulcer Bleeding

A Multi-center, Double-blinding, Parallel and Positive-controlled Phase III Clinical Trial for Efficacy and Safety Evaluation of Ilaprazole Sodium for Injection on Treatment of Prevention of Stress Ulcer Bleeding (Ilaprazole i.v. vs Esomeprazole, i.v.)

Last checked: Nov 19, 2026Latest source record: May 3, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 449 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

449

Actual

Start

Jul 16, 2021

Primary completion

Apr 28, 2022

Study completion Apr 28, 2022

Sponsor

Sponsor type
Industry
First posted
May 3, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 74 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the efficacy of the study drug (Ilaprazole Sodium for Injection) for potential effect on preventing stress ulcer bleeding in vulnerable population by comparing the radio of upper gastrointestinal bleeding when they are administered Ilaprazole Sodium for Injection and Esomeprazole Sodium for Injection respectively.

Conditions

  • Stress Ulcer Bleeding

Interventions

  • Esomeprazole 40mgDrug

    40 mg i.v. twice daily (q12h)

  • Ilaprazole SodiumDrug

    10 mg i.v. once daily, 20 mg i.v. in the first day.

  • Placebo 1Drug

    Physiologic saline for injection, 100 ml/bag, q24h, following Ilaprazole Sodium with a time interval of 12 h.

  • Placebo 2Drug

    Physiologic saline for injection, 100 ml/bag, q12h, dosing on the first day.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Preventing clinically significant gastrointestinal bleedingTime frame: Day 1 to Day 3
  2. Preventing clinically significant gastrointestinal bleedingTime frame: Day 1 and Day 2
  3. Preventing clinically significant gastrointestinal bleedingTime frame: Day 3
  4. Preventing clinically significant gastrointestinal bleedingTime frame: Day 1 to Day 3

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • Shanghai Jiaotong University Affiliate Ruijin Hospital

    Shanghai, Shanghai Municipality, China

  • The First Affiliated Hopspital of Xinjiang Medical University

    Ürümqi, Xinjiang, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.